Subscribe free

HPB & Spleen ·

Combination TACE and Apatinib Improves Survival in UHCC

Transarterial chemoembolization (TACE) with apatinib significantly enhances survival in patients with unresectable hepatocellular carcinoma (UHCC) compared to TACE alone.

  • Median progression-free survival was 6.1 months vs. 3.4 months (HR 0.45) and overall survival was 28.9 months vs. 24.0 months (HR 0.55).
  • At current drug prices, the cost-effectiveness ratio is $42,864/QALY, above the willingness-to-pay threshold, but drops to $30,650/QALY by 2025.

Successful central procurement could make this regimen not only clinically beneficial but also economically viable for broader use.

Clinical Trial, Phase III by Zhang Y, Wang X (…) Sun G et 2 al. in BMJ Open

© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

read the whole article in BMJ Open

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →